BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in GermanyPRNewsWire • 11/28/23
BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion StakeInvestors Business Daily • 11/07/23
4 Unique Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market DipThe Motley Fool • 11/04/23
BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over YearPRNewsWire • 11/01/23
BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive OfficerPRNewsWire • 11/01/23
U.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with AchondroplasiaPRNewsWire • 10/20/23
BioMarin to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ETPRNewsWire • 10/17/23
BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) MeetingPRNewsWire • 09/21/23
Investors should stick to the ‘late cycle playbook' and buy these sectors, says Morgan Stanley's Mike WilsonMarket Watch • 09/18/23
BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with AchondroplasiaPRNewsWire • 09/15/23
BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New YorkPRNewsWire • 09/11/23